Featured
-
-
Research Highlight |
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer
- Peter Sidaway
-
Review Article |
Global epidemiology of epithelial ovarian cancer
Ovarian cancer, accounting for 4.7% of cancer deaths in women in 2020, remains highly prevalent globally. Nonetheless, owing to changes in environmental exposures, the approach to preventive measures and disease classification, both incidence and mortality have been declining in economically developed countries since the early 2000s. Conversely, parts of Asia and eastern Europe have seen increases in the incidence of ovarian cancer over this period of time. In this Review, the authors summarize the epidemiology of ovarian cancer, including the roles of the various risk factors and the potential for prevention.
- Penelope M. Webb
- & Susan J. Jordan
-
Research Highlight |
Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer
- Diana Romero
-
Research Highlight |
Non-inferiority of simple versus radical hysterectomy in low-risk cervical cancer
- Diana Romero
-
Research Highlight |
Mirvetuximab soravtansine superior to chemotherapy in platinum-resistant epithelial ovarian cancer
- Peter Sidaway
-
Research Highlight |
Neoadjuvant chemoimmunotherapy is effective in locally advanced cervical cancer
- Diana Romero
-
Research Highlight |
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer
- Diana Romero
-
-
Research Highlight |
Survival benefit with second-line combination in endometrial cancer
- Diana Romero
-
-
-
-
-
-
News & Views |
First-line PARP inhibition in ovarian cancer — standard of care for all?
In 2018, the SOLO1 trial set a new standard of care with maintenance olaparib substantially extending progression-free survival (PFS) in women with newly-diagnosed BRCA1/2-mutated advanced-stage ovarian cancer. Herein, we summarize trials of first-line poly(ADP-ribose) polymerase (PARP) inhibition beyond BRCA1/2 mutations, including combination strategies, and discuss the optimum use of PARP inhibition in advanced-stage ovarian cancer.
- Susana N. Banerjee
- & Christopher J. Lord
-
-
-
-
Year in Review |
Advances in prediction for ovarian cancer treatment stratification
Breakthrough findings reported in 2018 provide the foundations for paradigm shifts in the care of patients with ovarian cancer. These results have implications for treatment in the first-line setting (with improved and refined use of established treatment modalities), firmly introduce concepts of consolidation and maintenance therapy, and enable more accurate prediction of drug sensitivity and resistance.
- Amit M. Oza
-
-
-
News & Views |
Steps towards effective gynaecological cancer screening
PapSEEK, a novel liquid-based cytology test, enabled the highly specific detection of endometrial and ovarian cancer in a retrospective study. Herein, I discuss potential applications of this tool, both for cancer screening of asymptomatic populations and for the early diagnosis of cancer in symptomatic women.
- Usha Menon
-
-
Comment |
Manifesto for global women's health
Women's health is more than reproductive health. Why does this phrase still need to be repeated? This commentary highlights the urgent need to encourage more women to lead, research, and educate to move beyond stereotypes and to ensure we push forward in improving the lives of women everywhere.
- Ophira Ginsburg
-
-
-
News & Views |
Novel molecular subtypes of cervical cancer — potential clinical consequences
The Cancer Genome Atlas Research Network recently published the most comprehensive, multi-omic molecular characterization of cervical cancers performed to date. The data reveal novel disease subtypes, and provide new insights into the aetiology and pathogenesis of cervical cancer. Importantly, the information obtained has potentially major clinical implications.
- Chris J. L. M. Meijer
- & Renske D. M. Steenbergen
-
-
-
-
Review Article |
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
The PARP inhibitor olaparib has been approved for clinical use in patients with ovarian cancer withBRCA 1/2 mutations; however, this agent, which can confer substantial improvements in patient survival might also be effective in those without a BRCA mutation. Here, the authors describe the potential for expanding the use of BRCA-mutation testing and PARP inhibition beyond those who are likely to have a BRCAmutation.
- Angela George
- , Stan Kaye
- & Susana Banerjee
-
-
Opinion |
Counselling framework for moderate-penetrance cancer-susceptibility mutations
The use of multigene panels for the assessment of cancer susceptibility is expanding rapidly in clinical practice. The appropriate management of individuals harbouring moderate-penetrance genetic variants in individuals referred for clinical testing is unclear. The authors of this Perspectives article provide a framework for clinical decision-making pending the development of a sufficient evidence base to document the clinical utility of the interventions for individuals with inherited moderate-penetrance gene mutations associated with an increased risk of cancer.
- Nadine Tung
- , Susan M. Domchek
- & Mark E. Robson
-
-
-
-
-
-
Opinion |
Can advanced-stage ovarian cancer be cured?
Patients with advanced-stage ovarian cancer are widely believed to have a dismal prognosis; however, around 20% of women with this disease survive beyond 12 years after treatment and are effectively cured. In this Perspectives, Steven Narod presents the case that this proportion could be substantially increased through the combination of maximal debulking surgery and intraperitoneal chemotherapy.
- Steven Narod
-
Year in Review |
Insights into strategies for optimizing ovarian cancer care
Advances in key areas of research have enabled improved outcomes for patients diagnosed with ovarian cancer in the past three decades. In 2015, this trend was maintained with important progress in areas such as guideline compliance, design of targeted approaches and molecular profiling.
- Robert L. Coleman
-
-
News & Views |
Limited use of the intraperitoneal route for ovarian cancer—why?
A recent objective study has demonstrated that the use of adjuvant platinum-based intraperitoneal chemotherapy in patients with small-volume residual advanced-stage ovarian cancer remains limited, despite the publication of several phase III trials demonstrating superior overall survival associated with this approach. Several factors might explain this far less than satisfactory state of affairs.
- Maurie Markman
-
-
Opinion |
HPV-FASTER: broadening the scope for prevention of HPV-related cancer
Human papillomavirus (HPV)-screening technologies and HPV vaccination are revolutionizing the management of cancers related to this virus, in particular, cervical neoplasms. At present, however, the effectiveness of these modalities is not optimal, owing to the limited scope of HPV-vaccination and cervical screening programmes. In this Perspectives, an international panel of experts describes for the first time a new campaign, termed 'HPV-FASTER', which aims to broaden the use of HPV vaccination coupled with HPV testing to women aged up to 30 years, and in some settings up to 50 years, with the aim of accelerating the reduction in the incidence of HPV infections and cervical cancer. The authors describe the evidence supporting this approach and details on how it might be implemented, discuss the opportunities—particularly in low-resource settings—and challenges associated with the strategy, and highlight key research gaps that need to be addressed in future studies.
- F. Xavier Bosch
- , Claudia Robles
- & Jack Cuzick
-
Research Highlight |
ADAMTS mutations predict sensitivity to chemotherapy in ovarian cancer
- Alessia Errico
-
-
News & Views |
Squamocolumnar junction ablation—tying up loose ends?
Despite the commercialization of HPV vaccines, cervical cancer remains a major cause of death, especially in developing countries. Recent data implicate a discrete population of cells within the cervical squamocolumnar junction in the pathogenesis of cervical precancerous lesions, indicating that ablation of these cells might reduce the rate of cervical cancer in high-risk populations.
- Michael Herfs
- & Christopher P. Crum
-
-